RNA
Atrium Therapeutics, Inc.
$13.09
+0.05
(+0.38%)
Mkt Cap
223.91M
Volume
291,689
52W Range
11.95-16.77
Sector
Healthcare
Beta
N/A
EPS (TTM)
-4.48
P/E Ratio
-3.29
Revenue (TTM)
18.62M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 18.62M |
| Net Income | (76.68M) |
| EPS | -4.48 |
| Free Cash Flow | (42.57M) |
| FCF / Share | -2.49 |
| Operating CF | (41.13M) |
| Total Assets | 278.35M |
| Total Debt | 3.67M |
| Cash & Equiv | 270.00M |
| Book Value | 207.29M |
| Return on Equity | -0.37 |
| Metric | Q1 2026 | Q4 2025 |
|---|---|---|
| Revenue | 19.64M | 859,000 |
| Net Income | (16.63M) | (48.07M) |
| EPS | -0.97 | -1.70 |
| Free Cash Flow | (33.24M) | (20.13M) |
| FCF / Share | -1.94 | -1.18 |
| Operating CF | (31.14M) | (19.25M) |
| Total Assets | 292.36M | 278.35M |
| Total Debt | 2.68M | 3.67M |
| Cash & Equiv | 267.85M | 270.00M |
| Book Value | 234.10M | 207.29M |
| Return on Equity | -0.07 | -0.23 |
RNA News
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1